Synonyms: BVL-GSK098
Compound class:
Synthetic organic
Comment: Alpibectir is being developed by BioVersys AG and GlaxoSmithKline as an oral treatment for tuberculosis (TB) in combination with ethionamide or prothionamide. Alpibectir targets bacterial transcriptional regulators and potentiates the activity of drugs used in the treatment of TB, in particular drugs that are activatable via the EthA pathway. It is one of the spiroisoxazoline class of compounds claimed in patent WO2019034700A1 [1].
|
|
Bioactivity Comments |
A combination of ethionamide + alpibectir has been shown to be active against EthA/EthR mutant strains of Mycobacterium tuberculosis, which represent 76% of ethionamide-resistant strains [2]. |